Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerReferences
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med. 2013; 368: 138-148
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014; 371: 424-433
- Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.N Engl J Med. 2017; 377: 352-360
- Enzalutamide with standard first-line therapy in metastatic prostate cancer.N Engl J Med. 2019; 381: 121-131
- A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.J Clin Oncol. 2019; 37: 2974-2986
- Apalutamide for metastatic, castration-sensitive prostate cancer.N Engl J Med. 2019; 381: 13-24
- Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis.J Urol. 2015; 194: 378-385
- The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis.Eur Urol. 2017; 72: 14-19
- Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial.Eur Urol. 2019; 75: 410-418
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet. 2018; 392: 2353-2366
NCCN clinical practice guidelines in oncology. [Internet]. Pennsylvania, EEUU: National Comprehensive Cancer Network (NCCN); 2020 [actualizado enero 2022; citado 17 marzo 2022]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.Eur Urol. 2021; 79: 263-282
- Oligometastases.J Clin Oncol. 1995; 13: 8-10
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet. 2019; 393: 2051-2058
- Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.N Engl J Med. 2015; 373: 737-746
- Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis.Eur Urol. 2019; 76: 115-124
U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [acces data 14 april 2022]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01957436.
- Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer. A secondary analysis of a randomized clinical trial.JAMA Oncol. 2021; 7: 555-563
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.J Clin Oncol. 2018; 36: 446-453
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-years results of a randomized phase II trial.J Clin Oncol. 2020; 38 (10-10)
- Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.JAMA Oncol. 2020; 6: 650-659
- Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials.J Clin Oncol. 2022; 40: 3377-3382
- Phase II trial of SBRT and androgen deprivation for oligometastases in prostate cancer.Int J Rad Oncol Biol Phys. 2021; 111: S59
- OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer.Eur Urol. 2021; 80: 405-414
- Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes.Clin Genitourin Cancer. 2017; 15: 623-632
- Recent advances in the management of hormone-sensitive oligometastatic prostate cancer.Cancer Manage Res. 2022; 14: 89-101
- Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness.Clin Genitourin Cancer. 2021; 19: 230-236
- Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial.Eur Urol. 2018; 74: 455-462
- Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. A meta-analysis.Am J Clin Oncol. 2020; 43: 73-81
- Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.Br J Radiol. 2020; 93: 1-9
- Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences.Clin Oncol R Coll Radiol G B. 2016; 28: 115-120
- Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses.Cancers (Basel). 2020; 12: 2153
- The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited.Eur Urol. 2021; 80: 632-640
- Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer.Int J Radiat Oncol Biol Phys. 2021; 109: 387-395
U.S. National Library of Medicine. ClinicalTrial.gov [Internet] U.S. National Library of Medicine; [citado 20 de mar de 2022]. Disponible en: https://clinicaltrials.gov
- Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.Radiat Oncol. 2014; 9: 135
- Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.Strahlenther Onkol. 2015; 191: 310-320
- The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases.Eur Urol Focus. 2021; 7: 241-244